Treatment of Massive Intrathecal Methotrexate Overdose by Ventriculolumbar Perfusion
- 9 August 1984
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 311 (6) , 386-388
- https://doi.org/10.1056/nejm198408093110607
Abstract
INTRATHECAL chemotherapy is now widely used in the prophylaxis and treatment of neoplasms that metastasize to the central nervous system. Over 20 years of experience with intrathecal methotrexate therapy has resulted not only in improved survival rates in some cancers1 2 3 but also in the recognition of a number of acute and chronic toxicities. Exposure to methotrexate in high concentrations or for sustained periods is clearly neurotoxic, and various dosage recommendations have been suggested to avoid neurotoxicity.4 , 5 Clinical studies indicate that adults should receive a maximal intrathecal dose of 12.5 mg of methotrexate to avoid acute clinical neurotoxicity.Cases of inadvertent . . .Keywords
This publication has 8 references indexed in Scilit:
- An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adultsBlood, 1984
- Intrathecal vincristine. Report of a fatal case despite CNS washoutCancer, 1983
- Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.Journal of Clinical Oncology, 1983
- Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdoseCancer, 1982
- The acute management of intrathecal methotrexate overdose: Pharmacologic rationale and guidelinesThe Journal of Pediatrics, 1981
- Combined modality therapy of acute lymphocytic leukemiaCancer, 1975
- Neurotoxicity and Elevated Cerebrospinal-Fluid Methotrexate Concentration in Meningeal LeukemiaNew England Journal of Medicine, 1973
- Subarachnoid Distribution of Drugs after Lumbar InjectionNew England Journal of Medicine, 1962